Senior Vice President CMC
Jo Craig is Senior Vice President CMC for NeRRe Therapeutics and uses her extensive experience, expertise and leadership to ensure delivery of the chemistry, manufacturing and controls (CMC) for Orvepitant through external development and supply organisations. Jo previously held the same role for KaNDy Therapeutics, a Women’s Health company, which was acquired by Bayer Pharmaceuticals in September 2020.
Prior to joining NeRRe, Jo spent over 30 years at GlaxoSmithKline where she was latterly VP of Technology & Strategy, Product Development & Supply. Her career has spanned many roles in CMC product development, achieving UK and global leadership. Specific successes include the CMC delivery of the sumatriptan portfolio for migraine and the dolutegravir portfolio for HIV. Jo went on to set up and lead a new global process robustness group at the interface of R&D and Manufacturing and has also headed the New Product Introduction Quality group.
Whilst at GSK, Jo also held the role ‘Observer’ on the NeRRe and KaNDy boards.
Jo holds a BPharm (first class honours) from the School of Pharmacy, University College, London and is a registered Pharmacist. She is a Fellow of the Royal Pharmaceutical Society, an Eminent Fellow of the Academy of Pharmaceutical Sciences (APS), UK and current Chair of the APS Board. Jo also contributes as a member of the Medicines Manufacturing Advisory Group (UK) and, as a former member of the Medicines Manufacturing Industry Partnership (MMIP), has been influential in aligning Pharma and UK Government on future areas for investment.